Cocrystal Pharma (COCP) Other Non-Current Assets (2010 - 2026)
Cocrystal Pharma (COCP) posted Other Non-Current Assets of $95000.0 for Q1 2026, little changed sequentially from $95000.0 in Q4 2025, and up 10.47% YoY from $86000.0 in Q1 2025.
Cocrystal Pharma (COCP) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Cocrystal Pharma has reported Other Non-Current Assets for 17 years, with the latest figure at $95000.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 10.47% year-over-year to $95000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95000.0 (up 10.47% YoY) and the FY2025 annual result came in at $95000.0, up 227.59% from the prior year.
- Other Non-Current Assets held at $95000.0 in Q1 2026 per COCP's latest filing, from $95000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $95000.0 in Q4 2025 and troughed at $29000.0 in Q2 2024.
- A 5-year average of $56176.5 and a median of $46000.0 in 2022 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets tumbled 36.96% in 2024, then jumped 227.59% in 2025.
- Over 5 years, Other Non-Current Assets stood at $46000.0 in 2022, then changed by 0.0% to $46000.0 in 2023, then sank by 36.96% to $29000.0 in 2024, then surged by 227.59% to $95000.0 in 2025, then changed by 0.0% to $95000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $95000.0, $95000.0, and $90000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Cocrystal Pharma | 15.65 Mn | 13.33 Mn | - | 114,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 114,000.00 |
| Mar 31, 2026 | 95,000.00 |
| Dec 31, 2025 | 95,000.00 |
| Sep 30, 2025 | 90,000.00 |
| Jun 30, 2025 | 88,000.00 |
| Mar 31, 2025 | 86,000.00 |
| Dec 31, 2024 | 29,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Mar 31, 2024 | 46,000.00 |
| Dec 31, 2023 | 46,000.00 |
| Sep 30, 2023 | 46,000.00 |
| Jun 30, 2023 | 46,000.00 |
| Mar 31, 2023 | 46,000.00 |
| Dec 31, 2022 | 46,000.00 |
| Sep 30, 2022 | 46,000.00 |
| Jun 30, 2022 | 46,000.00 |
| Mar 31, 2022 | 46,000.00 |
| Dec 31, 2021 | 46,000.00 |
| Sep 30, 2021 | 46,000.00 |